Paul A Friedman sold $14M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 24,800 shares at an average of $552.18, traded Dec 10, 2025, filed Dec 12, 2025.
Score components
- +15RoleDirector
- +25Trade size$13.7M at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.0%, 3m -22.2%, 6m -15.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-056794, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 10, 2025 | MOption exercise Common Stock10b5-1 | +24,800 | $15.80 | $392k | 211,964 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -624 | $547.75 | $342k | 211,340 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -535 | $548.51 | $293k | 210,805 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -409 | $549.99 | $225k | 210,396 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -4,316 | $550.93 | $2.4M | 206,080 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -7,193 | $551.67 | $4.0M | 198,887 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -5,533 | $552.74 | $3.1M | 193,354 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -5,001 | $553.83 | $2.8M | 188,353 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -1,029 | $555.00 | $571k | 187,324 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -160 | $555.39 | $89k | 187,164 | Dec 12, 2025 |
| Dec 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -24,800 | $0.00 | $0 | 24,800 | Dec 12, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $342k 664 shares | -5% | |
| 35Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,500 shares | -1% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $517k 1,042 shares | -9% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $2.9M 5,682 shares | -21% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $435k 844 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub Pres., R&D, and CMO | $212k 491 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.